Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: A pilot study  by Hammana, I. et al.
(2009) 128–134
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 8Dichotomy between postprandial glucose and lipid profiles in adults with
cystic fibrosis: A pilot study
I. Hammana a,f, L. Coderre a,d, S. Potvin a,c, M. Costa a, Y. Berthiaume c,d, A. Lavoie c,d,
J.-L. Chiasson a,d, E. Levy e,f, R. Rabasa-Lhoret a,b,c,e,f,⁎
a Diabetes and Metabolic Diseases Research Group, Research Centre hospitalier de l'Université de Montréal (CHUM) - Hôtel-Dieu, Montréal QC, Canada
b Montreal Diabetes Research Centre, Montreal, QC, Canada
c Cystic Fibrosis Clinic, CHUM - Hôtel-Dieu, Montréal, QC, Canada
d Department of Medicine, Université de Montréal, Montréal, QC, Canada
e Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada
f Department of Nutrition, Université de Montréal, Montréal, QC, Canada
Received 14 February 2008; received in revised form 28 August 2008; accepted 3 November 2008
Available online 11 December 2008Abstract
Background: Cystic fibrosis (CF) patients present a high incidence of glucose tolerance abnormalities. Altered insulin secretion combined with
recommended high-fat intake could be associated with dysregulation of glucose and lipid metabolism. We examined postprandial glucose and
lipid profiles during an oral glucose tolerance test (OGTT) and following a standardized high-fat test meal (TM).
Methods: Sixteen CF patients with normal glucose tolerance (NGT) or CF-related diabetes (CFRD) and 16 controls underwent a 4 h OGTT and a
TM. We then measured plasma glucose, insulin, free fatty acid (FFA) and triglyceride (TG) concentrations.
Results: CF patients presented higher glucose excursion compared to controls after the OGTT and TM. However, in CF patients, this excursion
was significantly reduced in both amplitude and length after the TM. The TM provoked a comparable increase in TG levels in both groups
whereas they remained stable during the OGTT. FFAs were suppressed similarly in both groups after both challenges.
Conclusion: CF is associated with abnormal glucose excursion in the presence of relatively normal lipid excursion. The rapid normalization of
glucose values after a mixed meal should be further explored and, if confirmed, might have significant implications for CFRD diagnostic.
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The cystic fibrosis (CF) adult population is characterized by a
very high incidence of glucose intolerance states [1]. Previous
studies by our group and others have documented decreased
insulin secretion with a possible contribution of altered insulin
sensitivity as the cause of glucose tolerance abnormalities in CF
patients [2,3]. Insulin also plays an important role in lipid meta-
bolism, tightly regulating plasma free fatty acid (FFA) levels by⁎ Corresponding author. Division of Endocrinology, Research Centre,
CHUM-Hôtel-Dieu 3850 Saint Urbain St. Montréal, Québec, Canada H2W
1T7. Tel.: +514 890 8000x14086; fax: +514 412 7204.
E-mail address: remi.rabasa-lhoret@umontreal.ca (R. Rabasa-Lhoret).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.11.002reducing adipose tissue mobilization and enhancing FFA
clearance [4]. Thus, abnormal insulin secretion in CF patients
could be associated with abnormal postprandial glucose and lipid
excursion.
CF is characterized by exocrine pancreatic insufficiency,
which leads to fat malabsorption [5,6]. To prevent malnutrition,
current guidelines recommend that CF patients have a higher
energy diet and fat intake (40% of total calories as fat) than
healthy peers [5,7], along with appropriate pancreatic enzyme
supplementation. Despite these recommendations, data on the
postprandial metabolic profile of CF patients are scarce, and most
glucose values are derived from the oral glucose tolerance test
(OGTT) rather than post-meal. To our knowledge there is few
available data about lipid excursion.d by Elsevier B.V. All rights reserved.
Table 1
Physical characteristics of CF patients and control subjects
Controls
N=16
CF-NGT
N=10
CFRD
N=6
Age (years) 24.8±4.2 28.5±10.5 27.0±8.6
Sex ratio (M/F) 9/7 6/4 4/2
Weight (kg) 66.7±9.1 64.6±11.6 56.±10.6*
BMI (kg/m2) 22.4±1.6 23.5±2.2 20.7±3.5*
Pancreatic enzyme supplementation 0% 50% 100%
A1c 0.050±0.002 0.052±0.005 0.066±0.007+
†
Fasting glucose (TM) (mmol/L) 5.0±0.3 5.3±0.4 6.4±0.8+†
Fasting glucose (OGTT) (mmol/L) 5.0±0.5 5.3±0.3 6.1±0.9*+
Insulin AUC 120 min (TM) (µU/ml) 4,804±2,229 4,351±2,314 3,731±1,824
Insulin AUC 120 min (OGTT) (µU/ml) 6,632±2,766 5,379±2,346 4,142±2,412*
Total cholesterol (mmol/L) 3.84±0.46 3.78±1.13 3.74±0.09
HDL-cholesterol (mmol/L) 1.35±0.38 1.20±0.22 1.41±0.48
LDL-cholesterol (mmol/L) 2.13±0.37 2.12±0.82 1.74±0.51
Fasting TG (mg/dl) 0.98±0.34 1.05±0.46 1.15±0.41
Fasting FFA (mEq/L) 0.35±0.12 0.32±0.16 0.46±0.22
CF-NGT: cystic fibrosis patients with normal glucose tolerance, CFRD: cystic fibrosis-related diabetes, BMI: body mass index, A1c: glycated hemoglobin, OGTT:
oral glucose tolerance test, TM: test meal, AUC: area under the curve; HDL: high-density lipoprotein, LDL: low-density lipoprotein, TG: triglyceride, FFA: free fatty
acids.
+Pb0.001 CFRD vs CF-NGT; †Pb0.001 CFRD vs Controls; *Pb0.05 CFRD vs Controls.
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with the recommended high-fat dietary intake, it is not known (i)
whether the high-glucose excursion observed after an OGTT
correctly represent that observed after a test meal (TM), and (ii)
whether CF patients present abnormal lipid excursion, i.e. the
inability to suppress FFA. The aim of this pilot study was to
examine postprandial glucose and lipid profiles during an OGTT
and a standardized high-fat TM in CF patients with or without
CF-related diabetes (CFRD) compared to a paired control group.
2. Methods
2.1. Subjects
Sixteen adult CF patients (N18 years of age) and 16 controls
with normal glucose tolerance (NGT) matched for age and sex
participated in this study. CF patients had either normal glucose
tolerance (CF-NGT) (N=10) or CFRD (diabetes duration 1–
3 years; N=6). The diagnosis of CFRD was based on 2
consecutive abnormal OGTT values (fasting valuesN7.0 mmol/L
or 2 hN11.0 mmol/L). To minimize the confounding effect of
chronic hyperglycemia, CFRDpatientswere included in the study
only if they were controlled by diet alone or if they could
discontinue hypoglycemic agents for at least 24 h without
significant short-term impact on diabetes control (fasting
glycemiab8.0 mmol/L).
Subjects were enrolled in the study if they met the following
criteria: 1) no antibiotic treatment in the previous 8 weeks, 2) no
weight fluctuation in the past 2 months (±2 kg), 3) no medi-
cations or conditions that could affect glucose metabolism such
as oral or intravenous steroids, growth hormone, Megace, or
pregnancy, 4) no clinical signs of dyspepsia or medication
known to alter gastric motility, 5) absence of liver disease, and 6)
appropriate enzyme and vitamin supplementation. The exclu-sion criteria were respiratory exacerbation in the previous
month, according to criteria published by the 1994 Cystic
Fibrosis Foundation Microbiology and Infectious Disease
Consensus Conference [8]. Exacerbation was identified by a
trained CF pneumologist on the day of the study. The protocol
was approved by the Research Ethics Committee of the Centre
Hospitalier de l'Université de Montréal (CHUM), and all
subjects signed a written consent form.
2.2. CF status
Pulmonary function was measured on the day of the OGTT,
using force expiratory volume (FEV)1 (L/sec) and predicted %
FEV1 (Medgraphic 1870, St. Paul, MN) as variables. Pancreatic
insufficiency was defined by current enzyme supplementation.
Five CF-NGTand all CFRD subjects were on pancreatic enzyme
replacement therapy (Table 1). The patients took pancreatic
enzymes only with the TM respecting their usual dosage for a
comparable meal. The dose was within recommended values for
all subjects [9].
2.3. Oral Glucose Tolerance Test (OGTT)
All subjects underwent a 4 h OGTT. After at least a 10 h fast,
they ingested a glucose solution in less than 5 min: 1.75 g/kg of
body weight to a maximum of 75 g according to American
Diabetes Association guidelines [10].
2.4. High fat test-meal
A standardized high-fat TM was given after at least a 10 h
fast. The objective was to obtain a high-fat mixed meal with
comparable carbohydrate content as provided by the OGTT.
Subjects ingested a high-fat meal consisting of a 500 ml milk
Fig. 1. Plasma glucose profile in response to a TM (A) and an OGTT (B) in CF
patients and controls. CF-normal glucose tolerance (CF-NGT); CF-related
diabetes (CFRD). *Pb0.05 CFRD vs. Controls; ΔPb0.05 CFRD vs. NGT;
ΨPb0.05 NGT vs. Controls.
Fig. 2. Total glucose area under the curve (AUC) of the OGTT and TM.
⁎Pb0.005 TM vs OGTT; ΔPb0.0001 NGT vs Controls for TM and OGTT;
€Pb0.0001 CFRD vs Controls for the TM and OGTT; ¥Pb0.0001 CFRD vs
NGT for TM and OGTT.
Fig. 3. Insulin profile in response to a TM (A) and an OGTT (B) in CF patients
and controls. CF-normal glucose tolerance (CF-NGT); CF-related diabetes
(CFRD).
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a slice of bread, in 10 min. The energy density of the meal was
940 Kcal and comprised 40 g proteins (17% of energy), 71 g
carbohydrates (30%) and 55 g lipids (53%).
2.5. Biochemical dosages
Blood samples were taken at times (T) 0, 60, 120, 180 and
240 min of the OGTT and the TM to measure plasma glucose,
insulin, FFA and triglyceride (TG) concentrations, while cho-
lesterol and high density lipoprotein (HDL) cholesterol were
measured only at T0 min. Glucose, insulin and FFA levels were
measured in duplicate. Plasma glucose was assessed at the time
of sampling with a Glucose Analyser (Beckman, Fullerton,
CA). Insulin levels were measured by radioimmunoassay
(Linco Research Inc., St. Charles, MO) while glycated
hemoglobin (A1c), an index of blood glucose control in the
previous month, was analyzed by immunoturbidimetric assay
with ADVIA1650 (Bayer Health Care Diagnostics, Toronto,
ON, Canada). Plasma fatty acids levels were measured by an
enzymatic colorimetric method (Wako Chemical, USA, Inc.,
Richmond, VA). Inter- and intra-assay percent coefficients of
variation were under 0.2 and 0.68%, respectively. Plasma totalcholesterol, HDL-cholesterol, triglyceride and glucose were
analyzed on the COBAS INTEGRA 400 (Roche Diagnostic,
Montreal, QC, Canada). Low-density lipoprotein cholesterol
was calculated according to the Friedewald equation.
Fig. 4. Triglyceride levels in response to a TM (A) and an OGTT (B) in CF-
patients and controls. CF-normal glucose tolerance (CF-NGT); CF-related
diabetes (CFRD). *Pb0.01 versus basal condition (time 0).
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The data are presented as means±SE. Both plasma glucose
and insulin area under the curve (AUC) were calculated by the
trapezoidal method. One-way ANOVA was performed to
analyze mean differences between the groups. When significant
differences were found, Fisher's post hoc test was used to
identify group differences. Significance was accepted at
Pb0.05.
3. Results
3.1. Subject characteristics
Basic demographic data on the 16 control subjects and 16 CF
patients, 10 CF-NGT and 6 CFRD, are reported in Table 1. All
control subjects had NGT. CFRD patients showed higher A1c and
lower body weight as well as body mass index compared to the
controls (Pb0.05) and CF-NGT subjects (Pb0.05).3.2. Plasma glucose during the TM and the OGTT
As reported in Table 1, CFRD patients presented signifi-
cantly higher fasting plasma glucose levels compared to the
controls and CF-NGT (Pb0.05). Irrespective of their glucose
tolerance status, both groups of CF patients showed signifi-
cantly higher glucose excursion compared to the controls
(Fig. 1A and B). In CF patients, glucose excursion had a similar
profile after both the OGTT and TM. However, despite similar
glucose intake, the magnitude of this excursion was reduced
during the TM both for peak values (pb0.05; Fig. 1A and B)
and the glucose AUC (Fig. 2). This was especially striking for
CFRD patients, who showed a 33% decrease of the glucose
AUC after the TM compared to the OGTT. Furthermore, and as
illustrated in Fig. 1, CFRD patients normalized their glucose
value more rapidly after the TM (T120 min) than after the
OGTT (T180 min). At T120 min, the post-challenge time
determining glucose tolerance status, there was a striking
difference between OGTT (12.40±1.85 mmol/L) and TM
glucose values (6.83±1.89 mmol/L; Pb0.001).
3.3. Insulin profile in response to the TM and OGTT
There was no significant difference in fasting insulin levels
between the 3 groups studied (Table 1) as well as between the
test days (data not shown). As illustrated in Fig. 3A and B,
administration of the OGTT or ingestion of a high fat meal
induced a time dependent increase in plasma insulin levels
(pb0.05), which followed a similar profile for both tests in both
groups of patients while the insulin AUC tended to be lower
during the TM than during the OGTT (Table 1).
3.4. Triglyceride levels in response to the TM and OGTT
In the fasting state, TG concentrations were similar in all
groups on both tests (Fig. 4A and B and Table 1). The standard-
ized high-fat TMprovoked a progressive and comparable increase
in TG in all groups, resulting in significantly higher levels at 4 h
compared to fasting values (controls 1.91±0.65 mmol/L; CF-
NGT 1.94±0.74 mmol/L; CFRD 1.91±0.89 mmol/L; Pb0.01).
On the other hand, and as reported in Fig. 1B, TG levels were not
significantly modified during the OGTT in any of the groups
studied.
3.5. FFA levels in response to the TM and OGTT
Fasting plasma FFA concentrations were not significantly
different between control subjects and either CF-NGT or CFRD
patients, whether they were measured on the day of the TM or
the OGTT (Fig. 5A and B). The OGTT and TM ingestion
provoked a time-dependent decrease in plasma FFA levels,
which followed a similar pattern in all 3 groups. This reduction
was followed by normalization of FFA levels by the end of the
4 h TM. However, differences were noted in the FFA profile
between the 2 tests. A maximum reduction of FFA levels was
reached at 60 min during the TM while it occurred between 120
and 180 min during the OGTT. Thus, the time to nadir seems to
Fig. 5. FFA levels in response to a TM (A) and an OGTT (B) in CF patients and
controls. CF-normal glucose tolerance (CF-NGT); CF-related diabetes (CFRD).
*Pb0.05 versus basal condition (time 0).
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surprising since insulin levels peak at 60 min on both tests.
4. Discussion
Because CF subjects present decreased insulin secretion and
have a recommended high dietary fat intake, we explored post-
prandial glucose and lipid profiles after a glucose load or a TM in
CF patients with and without diabetes. The results of our pilot
study indicate that CF patients present exaggerated glucose
excursions after both a TM and a glucose load. Despite com-
parable glucose intake during both challenges, glucose excur-
sion was significantly reduced after the TM. Surprisingly, and
despite lower insulin levels, we were unable to document any
abnormalities in FFA and TG responses between CF patients and
controls even after a high-fat TM. These results highlighted the
dichotomy between glucose and lipid profiles in CF patients.
Excessive postprandial glucose excursion is well-documen-
ted in CF patients [1,3]. The main reason is believed to be the
significant reduction of early insulin secretion already apparent
in CF-NGT patients [3]. While Moran et al. examined glucose
and insulin levels after a TM in CFRD patients [11], to our
knowledge, no study has directly compared glucose and FFA
profiles after an OGTT and a TM in CF patients. Interestingly,
and despite similar glucose loads during both challenges, CFpatients presented reduced glucose excursion (peak and AUC)
after the TM. This is especially striking for CFRD patients, who
showed a decrease of glucose AUC and plasma glucose levels at
120 min of the TM compared to the OGTT. It also contrasts with
type 2 diabetic patients who remain hyperglycemic at 120min of
the TM [12].
The different amplitudes of glucose excursion between the 2
conditions are probably multifactorial. It is well-known that a
high fat meal can delay gastric emptying, leading to a shallower
rise in plasma glucose after the TM compared to the OGTT [13].
This could be important since severely affected CF individuals
have a higher rate of delayed gastric emptying [14,15] while the
opposite has been reported in less affected patients [16].
Alternatively, it could be due to differential incretin secretion
between the 2 conditions. Incretins play an important role in
glucose homeostasis, especially in the postprandial state. Since
the TM is a better stimulus than the OGTT, it leads to increased
gastric inhibitory peptide (GIP) and glucagons-like peptide
(GLP)-1 concentration after the meal [17]. CF patients present
lower GLP-1 and GIP plasma concentrations compared to
controls during an OGTT and these alterations may participate
in the exaggerated glucose excursion observed in these subjects
[18]. The relative contributions of abnormal gastric emptying and/
or hormonal responses to glucose excursion after the TM require
further exploration.
Blunted glucose excursion after the TM could also be
explained by better suppression of postprandial hepatic glucose
production. This process is a major determinant of glucose
excursion [19] and is mainly regulated by early insulin secretion
and glucagon suppression [20]. Recently, Hardin et al. reported
reduced insulin-mediated suppression of gluconeogenesis in CF
patients with abnormal glucose tolerance compared to those with
NGT [21,22]. Furthermore, in CF patients, the deterioration of
glucose tolerance status is also paralleled by a reduction of
glucose-mediated glucagon suppression [18,23]. Together, these
results indicate that alteration of glucagon secretion may con-
tribute to the rapid rise of postprandial glucose in CF patients. Our
results demonstrated reduced glucose excursion in CF patients
after the TM. Since insulin secretion was reduced to a similar
extent in all groups, it suggests that CF patients have better
suppression of hepatic glucose production after the TM than after
the isolated glucose challenge. This could be due to the potent
stimulatory effects of nutrients on GLP-1, a major inhibitor of
glucagon secretion [20]. Better glucagon suppression could also
explain the more rapid decrease in postprandial glucose after the
TM compared to the OGTT.
The postprandial glucose profile of CF patients is character-
ized by an abrupt rise in plasma glucose followed by rapid
normalization [3,24], a pattern widely different than that usually
seen in type 2 diabetic patients [25]. The present pilot study
extends this observation to a mixed meal, a condition in which
postprandial glucose excursion is blunted and normalization rapid
(Fig. 1). Our finding has major implications if random post-
prandial glucose values are used to screen for diabetes and it
probably explains the very low sensitivity of random blood glu-
cose measurement to detect new cases of CFRD [26]. This ob-
servation suggests that the OGTTshould bemaintained as the key
133I. Hammana et al. / Journal of Cystic Fibrosis 8 (2009) 128–134test to detect new cases of CFRD [1,3]. Recently, continuous
glucose monitoring revealed pathological glucose excursion,
even in CF-NGT patients [27]. Because of their unique post-
prandial glucose profile, continuous glucose monitoring may
provide an additional tool to more precisely investigate CF
patients [27].
As already reported, CF patients have normal fasting plasma
FFA concentration [28]. Importantly, FFA suppression after the
OGTTand theTMwas comparable to that in control subjects. This
contrasts with type 2 diabetic subjects who present reduced
insulin-mediated FFA suppression during the OGTT [29]. Fur-
thermore, and in contrast to glucose metabolism, we could not
observe any difference in FFA profile between CF-NGT and
CFRD after the TM or the OGTT, which is somewhat surprising
considering that CF patients showed reduced insulin secretion.
These findings do not preclude abnormalities that could have been
detected either with a longer study period after the TM or a more
detailed fatty acid profile [30]. They suggest, however, that insulin
levels remain sufficiently high to inhibit lipolysis and stimulate
lipogenesis (Fig. 5A and B). The postprandial lipid profile also
suggests that, in contrast to type 2 diabetes, in whom lipotoxicity
could be involved in both beta-cell failure and insulin resistance
[31,32], there is a low probability that such a phenomenon is
implicated in the development of CFRD. Thus, in CF patients,
deterioration of glucose metabolism does not seem to be
associated with a parallel deterioration of insulin-mediated FFA
suppression.
We investigated a limited number of stable patients to avoid
various confounding factors. However, it remains possible that, in
more severely affected subjects, glucose and FFA metabolism
may be regulated differently. Furthermore, CF patients present
significant lipid malabsorption, which is not totally palliated by
pancreatic enzyme supplementation, andwe cannot rule out that it
may have affected our results. Insulin is also the primary regulator
of protein metabolism, controlling both anabolic and catabolic
pathways. Thus, the reduced insulin secretion seen in CF patients
might have its most clinically significant impact on fat free mass
maintenance [30,33].
In conclusion, the present pilot study indicates that CF patients
show abnormal postprandial glucose (but not lipid) excursion.
Despite the overall similarity of blood glucose and insulin profiles
after the OGTT and TM, we noted intriguing differences, with a
better glucose profile after the mixed meal, indicating better
suppression of hepatic glucose production. Postprandial glucose
homeostasis should be further characterized in a larger group of
CF patients.
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